1601. Effect of Preemptive Rituximab Therapy on Epstein–Barr Reactivation in Allogenic Hematopoietic Stem Cell Pediatric Transplants

BACKGROUND: Children with Epstein–Barr virus (EBV) viremia after hematopoietic stem cell transplantation (HSCT) are at increased risk of post-transplant lymphoproliferative disease (PTLD). Our aim was to assess whether pre-emptive rituximab reduced EBV-viral load (EBV-VL) and the risk of developing...

Descripción completa

Detalles Bibliográficos
Autores principales: Catho, Gaud, Scheel, Daniel, Teira, Pierre, Renaud, Christian, Kakinami, Lisa, Ovetchkine, Philippe, Autmizguine, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254397/
http://dx.doi.org/10.1093/ofid/ofy210.1429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254397/
http://dx.doi.org/10.1093/ofid/ofy210.1429

Ejemplares similares